Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis
- 1 February 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Clinical Practice Rheumatology
- Vol. 3 (2), 86-95
- https://doi.org/10.1038/ncprheum0424
Abstract
Inflammatory responses to cell-associated or tissue-associated immune complexes are key elements in the pathogenesis of several autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus and immune thrombocytopenic purpura. Effector cells, such as monocytes, macrophages and neutrophils, bind immune complexes in a process mediated by Fcgamma receptors, and these cells then initiate inflammatory reactions that lead to tissue destruction. Rituximab is an anti-CD20 monoclonal antibody that suppresses inflammation effectively in autoimmune diseases. It was initially approved by the FDA for the treatment of B-cell lymphomas and later for rheumatoid arthritis refractory to anti-tumor necrosis factor therapies. Rituximab is hypothesized to suppress disease injury in autoimmune diseases by promoting rapid and long-term elimination of circulating and possibly lymphoid-tissue-associated B cells. We suggest, however, that a different mechanism may underlie much of the therapeutic action of rituximab in autoimmune diseases: binding of tens of thousands of rituximab-IgG molecules to B cells generates decoy sacrificial cellular immune complexes that efficiently attract and bind Fcgamma receptor-expressing effector cells, which diminishes recruitment of these effector cells at sites of immune complex deposition and, therefore, reduces inflammation and tissue damage.Keywords
This publication has 59 references indexed in Scilit:
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- B Cell-Targeted Therapy for Rheumatoid ArthritisDrugs, 2006
- A shift in the balance of inhibitory and activating Fcγ receptors on monocytes toward the inhibitory Fcγ receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritisArthritis & Rheumatism, 2004
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeysTransplant Immunology, 2003
- Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular LymphomaJournal of Clinical Oncology, 2003
- Evolving concepts of rheumatoid arthritisNature, 2003
- C1q-Binding Immunoglobulin G in MRL/I Mice Consists of Immune Complexes Containing Antibodies to DNAClinical Immunology and Immunopathology, 1995
- Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.Annals Of The Rheumatic Diseases, 1986
- Defective Reticuloendothelial System Fc-Receptor Function in Systemic Lupus ErythematosusNew England Journal of Medicine, 1979